Duke Clinical Research Institute, Duke University, Durham, NC 27705, USA.
J Pediatr. 2011 May;158(5):780-3. doi: 10.1016/j.jpeds.2010.10.042. Epub 2010 Dec 16.
To conduct a systematic review to assist the United States Secretary of Health and Human Services Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC) to determine whether Hemoglobin H screening should be included among the core recommended conditions for newborn screening.
We identified 21 articles in MEDLINE from 1989 to March 2010 that provided evidence regarding screening, treatment, and outcomes associated with Hemoglobin H disease.
In California, newborn screening has identified 9 cases per 100 000 of deletional hemoglobin H disease and 0.6 cases per 100 000 of nondeletional hemoglobin H disease. Five cases of hemoglobin Bart's hydrops fetalis syndrome were also identified in over ten years of screening for Hemoglobin H disease. Although Hemoglobin H disease is associated with a wide range of morbidity, no studies were found that evaluated the benefits of early identification and treatment.
The SACHDNC found the data insufficient to recommend that states adopt newborn screening for Hemoglobin H disease.
进行系统回顾,以协助美国卫生与公众服务部新生儿和儿童遗传性疾病顾问委员会(SACHDNC)确定是否应将血红蛋白 H 筛查纳入新生儿筛查的核心推荐条件。
我们在 1989 年至 2010 年 3 月期间从 MEDLINE 中确定了 21 篇文章,这些文章提供了与血红蛋白 H 病相关的筛查、治疗和结局的证据。
在加利福尼亚州,每 10 万名新生儿中筛查出 9 例缺失型血红蛋白 H 病,每 10 万名新生儿中筛查出 0.6 例非缺失型血红蛋白 H 病。在筛查血红蛋白 H 病的十多年中,还发现了 5 例血红蛋白 Bart's 胎儿水肿综合征。尽管血红蛋白 H 病与广泛的发病率有关,但没有研究评估早期发现和治疗的益处。
SACHDNC 认为数据不足以推荐各州采用新生儿血红蛋白 H 病筛查。